Company intelligence / Profile preview
Accure Therapeutics
- Ownership
- Private
- Employees
- ~49
- Development stage
- Phase 2
Overview
Accure Therapeutics is a private translational neuroscience R&D company based in Barcelona, Spain. Its lead program ACT‑01 (now OCS‑05), licensed to Oculis, achieved positive results in a Phase II trial for acute optic neuritis with no serious adverse events. The company has two additional programs targeting Parkinson's disease and epilepsy at earlier stages of development. Accure focuses on developing first-in-class small molecule drugs that address unmet needs in central nervous system disorders through innovative mechanisms and strategic partnerships.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (new chemical entities)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Accure Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accure Therapeutics.